The FDA’s Pharmacy Compounding Advisory Committee (PCAC) holds a meeting on July 24 to consider whether certain peptides should be added to a permitted list for production by compounding pharmacies. Multiple outlets report that the committee largely votes in favor of allowing several peptides—despite opposition or concerns from FDA agency scientists and the agency’s own stance.
According to the reports, the committee reviews evidence and hears from agency staff, followed by public comments. The peptides discussed include BPC-157, KPV, TB-500, and MOTS-C. The Hill reports that the committee breaks with agency scientists, voting to add these peptides to the list of substances compounding pharmacies can make, even as concerns are raised about the lack of demonstrated benefits.
Gizmodo similarly describes the committee as clearing the way for multiple previously banned peptides to be produced by compounding pharmacies, based on the committee’s largely favorable vote. TIME.com characterizes the decision as the committee voting on whether compounding pharmacies can legally dispense certain peptides.
The outlets collectively indicate the vote is a regulatory step for compounding allowances, while disagreements remain over the underlying evidence and benefit claims.
